No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home REAL ESTATE

TRIMTECH Therapeutics raises €28.6 million for treatment of neurodegenerative diseases

EU Startupsby EU Startups
March 6, 2025
Reading Time: 3 mins read
in REAL ESTATE, UK&IRELAND
Share on FacebookShare on Twitter

Cambridge-based TRIMTECH Therapeutics, a BioTech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, announced the closing of its €28.6 million Seed funding round.

The financing was led by Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon.

Nicola Thompson, CEO, TRIMTECH Therapeutics, said: “This oversubscribed financing round and the outstanding quality of our investor syndicate is a great endorsement of TRIMTECH’s unique approach to targeting the selective removal of aggregated proteins that underpin so many CNS diseases, and recognises our impressive scientific foundations and world class team. We extend our thanks to all of our supporters and look forward to working with the new Board members, as we now push forward with progressing the pipeline.”

Founded in 2023, TRIMTECH Therapeutic’s mission is to create novel small molecule degraders of protein aggregates that will combat neurodegenerative and inflammatory diseases including Alzheimer’s disease.

It was founded by CIC and DDF in conjunction with their joint entrepreneur-in-residence, Damian Crowther, and academic Co-founders Leo James (MRC Laboratory of Molecular Biology) and Will McEwan (UK Dementia Research Institute at the University of Cambridge).

The company’s proprietary degrader technology is focused on delivering potent CNS-penetrant small molecule heterobifunctional degraders and glues, which can rapidly remove disease-causing protein aggregates. Potent and selective removal of these toxic aggregates leaves the functional form of the target protein intact and able to support healthy cellular function.

TRIMTECH’s approach is based on more than 15 years of work by Dr Leo James and Dr William McEwan, elucidating the function and mechanism of action of the novel E3-ligase, TRIM21.

TRIMTECH is leveraging the innate properties of the E3 ubiquitin ligase TRIM21 to selectively and potently degrade protein aggregates associated with a range of diseases which are not well served by current TPD approaches. This approach harnesses TRIM21’s unique properties in the form of the Company’s TRIMTAC degrader molecules to develop medicines that address the needs of large patient populations with limited treatment options.

TRIMTECH has also appointed the following leading life science executives to the Board of Directors:

  • Michael Anstey, Partner at Cambridge Innovation Capital)
  • Laurence Barker, Partner at SV Health Investors (SV)
  • Hakan Goker, Managing Director at M Ventures
  • Jeffrey Moore, President at MP Healthcare Venture Management
  • Marie-Claire Peakman, Partner at Pfizer Ventures.

Laurence Barker, Partner, SV Health Investors’ Dementia Discovery Fund, said: “The team at DDF is thrilled to co-lead the creation of TRIMTECH to advance its TRIMTAC platform, which harnesses TRIM21’s unique ability to degrade aggregated proteins while preserving functional monomers. While targeted protein degradation has revolutionised drug discovery, effective clearance of protein aggregates remains a major challenge. TRIMTECH’s differentiated approach directly addresses this gap, opening new possibilities for treating neurodegenerative conditions and beyond.”

Michael Anstey, Partner, Cambridge Innovation Capital, said: “CIC is proud to have been part of the creation of TRIMTECH and co-led this financing round. With over 55 million people affected by Alzheimer’s and millions more battling other neurodegenerative disorders, this groundbreaking innovation has the potential to transform the course of treatment for these patients.”

The investment will support further development of the Company’s growing pipeline of potent, CNS penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs.

The pipeline is focused around the development of treatments for severe neurodegenerative and inflammatory disorders, including Alzheimer’s and Huntington’s disease.

Read the orginal article: https://www.eu-startups.com/2025/03/trimtech-therapeutics-raises-e28-6-million-for-treatment-of-neurodegenerative-diseases/

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

DACH

NTT to launch and list data center REIT in Singapore

May 9, 2025
FINTECH

Irish startup Axe lands €1.5 million to supercharge logistics teams with AI agents

May 9, 2025
Plasmon of interest to Aurelius and Newlat Food
DACH

Plasmon of interest to Aurelius and Newlat Food

May 9, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Venture capital investments top €1.3bn in 208 rounds as of Sep30  in Italy. They were €1.5 in all 2023. The new BeBeez Report

Venture capital investments top €1.3bn in 208 rounds as of Sep30 in Italy. They were €1.5 in all 2023. The new BeBeez Report

October 28, 2024
Next Post

Builder.ai founder and 'chief wizard' Sachin Dev Duggal steps down as CEO of Microsoft-backed unicorn

Purpose-led olive oil business Citizens of Soil secures €2.1 million

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart